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ABSTRACT 
The model amyloid peptide AAKLVFF was expressed as a His-tagged fusion protein with the immunoglobulin-
binding domain B1 of streptococcal protein G (GB1), a small (56 residues), stable, single-domain protein. We show 
that expression of this model amyloid peptide is possible, and is not hindered by aggregation. Formylation side 
reactions during the CNBr cleavage are investigated via synthesis of selectively formylated peptides. 
Expression of proteins using recombinant DNA 
methods is now ubiquitous, however expression of 
amyloid-forming proteins is potentially complicated by 
aggregation of the peptide during or after expression. 
Indeed, short amyloid forming segments can drive a non-
fibrillizing protein into the amyloid state. This was shown 
by Teng and Eisenberg who demonstrated that when 6-8 
residue fragments from amyloid-forming human proteins 
tau, -synuclein, PrP prion and amyloid  (A ) were 
inserted into a region of the enzyme RNase A amyloid 
formation occured. 
1
 Baxa et al. showed that fusion of the 
Ure2p prion protein with various proteins led to amyloid 
formation.
2
 The functions of the proteins (barnase, 
carbonic anhydrase, glutathione S-transferase and green 
 
fluorescent protein) were not substantially influenced 
showing that they retained their native structures. 
Amyloid fibrils have been used as scaffolds to present 
proteins such as cytochrome c, which retains its function 
on fibrils formed from a fusion construct with the amyloid 
forming SH3 domain.
3
 It is therefore of great interest to 
determine methods by which amyloid-forming short 
peptides can be expressed without driving amyloid 
assembly of the host protein in the fusion construct. 
 
The Hamley group have recently investigated the self-
assembly of peptide NH2-AAKLVFF-COOH in detail. 
4-7
  
This peptide is based on sequence A (16-20), KLVFF, 
from the amyloid  peptide, extended at the N terminus 
with two hydrophobic alanine residues. In water at 
sufficiently high concentration, this peptide forms twisted 
fibrils (as observed by TEM and cryo-TEM),
4, 6, 7
 whereas 
in methanol it forms nanotubes.
5-7
 Both these structures 
have also been reported for the related peptide A (16-22), 
KLVFFAE, by varying pH in aqueous solution.
8, 9
 The 
formation of -sheet structures in both solvents has been 
confirmed by FTIR, x-ray diffraction experiments in 
solution and circular dichroism (CD) spectroscopy on 
dried films.
4-7
 In dilute solution, the CD spectra reveal the 
absence of -sheet ordering but instead show features of a 
disordered conformation with a possible contribution 
from aromatic stacking interactions resulting from the 
phenylalanine residues. Solution NMR experiments were 
used to examine the solubility of the peptide in the two 
solvents, and to determine the critical aggregation 
concentration.
7
  
 
In the present paper, we report on the expression of 
AAKLVFF using a recombinant protein. This work was 
motivated by the desire to explore the synthesis of the 
peptide on a larger scale using appropriate hosts (eg. 
bacteria) and this work provides proof-of-concept of this. 
It is noted that the cyanogen bromide cleavage step leads 
to formylated peptide, and the nature of the formylated 
product was investigated in detail via synthesis of 
AAKLVFF formylated either just at the N terminus or 
additionally at the K residue. This indicates that CNBr 
produces a peptide with backbone formylation at the N 
terminus. Formylation at the -amino group in lysine was 
achieved by blocking the peptide N terminus in azido-
AAKLVFF. Formic acid /acetic anhydride did not give a 
formylated product, however, successful formylation was 
achieved with p-nitrophenol in a borate buffer (pH=10) / 
acetonitrile (1 : 1). Formylation of peptides and proteins 
has been investigated previously,
10-12
 however we are not 
aware of prior reports on this in the preparation of 
recombinant amyloid-type peptides. 
 
We used the GB1 fusion protein domain to express the 
model amyloid forming peptide AAKLVFF. 
Theoretically, cleaving the GB1-AAKLVFF fusion 
protein sequence by CNBr leads to sequences shown in 
Table 1, based on the UniProt Knowledgebase (Swiss-
Prot and TrEMBL).
13
 The corresponding peptide masses 
([M+H]
+
) from the sequence are also shown in Table 1. 
 
mass peptide sequence 
6024.4586 
HIAAGACCTTTACAGTTACT 
GAACATATGGCGGCGAAACT 
GGTGTTCTTTTAAGGATCCK 
TFTVTEHM 
5229.8631 
GGTACCATGGGCAGCAGCCA 
TCATCATCATCATCACACTT 
ACAAATTAATCCTTAATGGT M 
795.4763 AAKLVFF 
 
Table 1 Theoretical analysis of peptide masses ([M+H]
+
) 
cleaved from GB1-AAKLVFF 
 
The ESI-MS spectrum of the product obtained from 
RP-HPLC was compared with that of synthetic 
AAKLVFF, revealing the [M + H]
+ 
peak 795.4767 
(genetic) / 795.4765 (synthetic), (calc. 795.4771) and the 
doubly protonated peak [M+2H]
+
 at 398.2419 (genetic) / 
398.2418 (synthetic) (calc. 398.2426) in both spectra (SI 
Fig.1). In addition, fragmention analysis confirmed the 
sequence AAKLVFF. However, an ion at m/z 851.6071 
was also detected in the mass spectrum of the cleaved 
sequence AAKLVFF corresponding to an additional mass 
of 56 Da which is consistent with formylation of both 
primary amines by the formic acid.  
 
In order to investigate the formation of formylated 
byproducts in more detail, formylation of a sample of 
AAKLVFF in 98% formic acid was conducted in the 
presence of acetic anhydride
10
 in addition to a control 
experiment which consisted of the formylation of 
synthetic AAKLVFF in 70% formic acid with an excess 
of cyanogen bromide. The experiments were both 
monitored by RP-HPLC and after 6 hours the formylation 
using 98% formic acid displayed a new peak at 10.03 min 
(Peptide I, Scheme 1) whereas, in the control experiment, 
a new peak was observed at 10.59 min after 7 days 
(Peptide II) as shown in SI Fig 2. 
 
 
Scheme 1. Formylation of peptide AAKLVFF to give 
peptides I and II. 
 
 
Analysis of the fragmentation peaks in the mass 
spectrum of peptide I revealed the [M+H]
+
 peak 823.4708 
(a) (b)
(c)
(calc. 823.4720) indicating that it was the mono-
formylated product, formylated at the backbone N 
terminus (Scheme 1).  
 
In order to investigate further the single selective 
formylation reaction, the peptide azido-AAKLVFF III 
blocked at the N-terminus with 3-azidopropanoic acid 
which contained only the primary amine on the lysine 
side-chain was synthesized (Scheme 2). In this case, 
formylation was not observed in 98% formic acid /acetic 
anhydride, however, successful formylation to produce 
peptide IV was achieved based on a method reported by 
Dempsey,
10
 using p-nitrophenol in a borate buffer 
(pH=10) / acetonitrile mixture (1 : 1) (Scheme 2). As a 
consequence, formylation of peptide AAKLVFF was 
attempted using these same conditions and the isolated 
product displayed an identical retention time (tR) with 
peptide II. The ESI-MS spectrum of the product showed 
the [M + H]
+ 
ion at 851.4673, thereby confirming bis-
formylation, both on the backbone and on the lysine side-
chain (calc. 851.4669). 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Formylation of peptide azido-AAKLVFF (III) to 
produce peptide IV. 
 
Figure 1.  Comparison of 1H-NMR (DMSO-d6) of genetic and 
synthetic AAKLVFF fragments, Peptide I (formylation on 
backbone) and Peptide II (formylation on backbone and lysine 
side chain). 
 
The genetic AAKLVFF was isolated from its mono-
formylated (Peptide I) and bis-formylated (Peptide II) 
analogues following repeated semi-preparative HPLC (SI 
Fig. 2b). All of the 
1
H-NMR data have been analysed 
(Figure 1), and are reported in the experimental section 
(Supporting Information). 
 
The self-assembly of peptides I, II and III was studied 
using FTIR spectroscopy, circular dichroism (CD) and 
cryogenic-transmission electron microscopy (cryo-TEM). 
We have previously reported in detail on the self-
assembly of synthetic AAKLVFF in water, using these 
techniques. Fig. 2 shows representative cryo-TEM images 
of these peptides, showing self-assembly into fibrils. Due 
to insolubility in water, peptide II was dissolved in a 1:1 
water/acetonitrile mixture. Peptide I exhibits short rigid 
fibrils, which at high magnification can be seen to be 
twisted. In contrast, peptide II shows longer, less straight 
fibrils which at higher magnification do not, in general, 
show twisting. The difference in morphology of these 
samples highlights the influence of packing and 
electrostatic interactions on the intermolecular stacking of 
the -sheets. Peptide III formed a very dense network of 
extended fibrils as shown in Fig.2c. It was also necessary 
to dilute this sample (compared to conditions used for I 
and II) in order to image the fibrillar network by cryo-
TEM. The presence of the azido group appears to enhance 
fibrillisation of AAKLVFF, possibly due to enhanced 
hydrophobic interactions. 
 
Figure 2. Cryo-TEM images (a) mono-formylated peptide I (2 
wt% in H2O), (b) bis-formylated peptide II (2 wt%  in 1:1 
H2O:CH3CN) , (c) azido-AAKLVFF, peptide III (0.012 wt% in 
H2O). The scale bars represent 200 nm. 
 
 
These fibrils are rich in -sheet as shown by the 
representative FTIR spectrum for peptide III in Fig.3a 
(and our previous extensive characterization of 
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AAKLVFF
4, 6, 7
). FTIR spectroscopy in the amide I region 
provides information on secondary structure. Fig.3a 
shows a peak at 1625 cm
-1
 associated with -sheet and a 
smaller peak at 1672 cm
-1
 often ascribed to the presence 
of TFA counterions.
14-16
 The CD spectrum (Fig.3b) 
measured under the same conditions shows a maximum at 
around 190 nm and abroad minimum around 210 nm, also 
consistent with -sheet structure. 
 
 
Figure 3. (a) FTIR and (b) CD data for an 0.98 wt% solution of 
peptide III in D2O. 
 
In summary, we have shown that genetic engineering 
methods can be used to produce a model amyloid peptide. 
CNBr cleavage leads to a product that is formylated at the 
N terminus and on the lysine -amino group. Self-
assembly of mono- and bis- formylated AAKLVFF leads 
to fibrils with distinct structures. A model system with an 
azido-functionalized N terminus (blocked for formylation 
studies) also self-assembles, with a much greater density 
of fibrils than for the other peptides and with well 
resolved -sheet features in the FTIR and CD spectra. 
The azido-functionalized peptide is also under 
investigation as a building block to construct three 
dimensional chemical structures, e.g. star-type 
macromolecules or peptide-functionalized hyperbranched 
molecules, by “click” chemistry. 
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